Financial Comparison: Medgenics (GNMX) & Mateon Therapeutics (MATN)

Mateon Therapeutics (OTCMKTS: MATN) and Medgenics (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Mateon Therapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Medgenics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mateon Therapeutics and Medgenics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
Medgenics 0 1 2 0 2.67

Mateon Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 641.29%. Medgenics has a consensus price target of $7.50, indicating a potential upside of 410.20%. Given Mateon Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Mateon Therapeutics is more favorable than Medgenics.

Profitability

This table compares Mateon Therapeutics and Medgenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -224.38% -186.53%
Medgenics N/A -163.88% -130.14%

Insider & Institutional Ownership

8.6% of Mateon Therapeutics shares are held by institutional investors. Comparatively, 21.0% of Medgenics shares are held by institutional investors. 2.3% of Mateon Therapeutics shares are held by company insiders. Comparatively, 15.2% of Medgenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mateon Therapeutics and Medgenics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A N/A ($0.55) -0.49
Medgenics N/A N/A -$41.90 million ($0.96) -1.53

Medgenics is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Mateon Therapeutics beats Medgenics on 5 of the 9 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

About Medgenics

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply